Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex

Brain Research

Volumn 759, Issue 2, 1997, Pages 205-212

  Lindefors, N ^a   Barati, S ^a   O'Connor, W T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Aminobutyric acid (GABA); 5 Hydroxyindoleacetic acid (5 HIAA; Dopamine; Ketamine; Microdialysis; Prefrontal cortex

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; KETAMINE; SEROTONIN;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG EFFECT; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

ANIMALS; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; KETAMINE; MALE; MICRODIALYSIS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 0030750142     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00255-2     Document Type: Article

References (43)

1. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E. Jr., Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex. J. Neurosci. 16:1996;19-30.
2. Björklund A., Lindvall O. Dopamine-containing systems in the CNS. Björklund A., Hökfelt T. Handbook of Chemical Neuroanatomy, 2, Classical Transmitters in the CNS, Part I. 1984;55-122 Elsevier, Amsterdam.
3. Cohen R.M., Semple W.E., Gross M., Nordahl T.E., DeLisi L.E., Holcomb H.H., King A.C., Morihisa J.M., Pickar D. Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci. 40:1987;2031-2039.
4. Deakin J.F.W., Slater P., Simpson M.D.C., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52:1989;1781-1786.
5. 3H]GABA release from cultured cortex neurons. Eur. J. Pharmacol. 143:1987;287-290.
6. Goldstein M., Deutch A.Y. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 6:1992;2413-2421.
7. Hondo H., Yonezawa Y., Nakahara T., Nakamura K., Hirano M., Uchimura H., Tashiro N. Effects of phencyclidine on dopamine release in the prefrontal cortex; an in vivo microdialysis study. Brain Res. 633:1994;337-342.
8. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
9. Jedema H.P., Moghaddam B. Characterization of excitatory amino acid modulation of dopamine release in the prefrontal cortex of conscious rats. J. Neurochem. 66:1996;1448-1453.
10. Joyce J.N. The dopaminergic hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology. 112(Suppl. 1):1993;S16-34.
11. Kashiwa A., Nishikawa T., Nishijima K., Umino A., Takahashi K. Dizolcipine (MK-801) elicits a tetrodotoxin-sensitive increase in extracellular release of dopamine in rat medial prefrontal cortex. Neurochem. Int. 26:1995;269-279.
12. Kehr J., Ungerstedt U. Fast HPLC estimation of γ-aminobutyric acid in microdialysis perfusates: effect of nipecotic and 3-mercaptopropionic acids. J. Neurochem. 51:1988;1308-1310.
13. Kim J.S., Kornhuber H.H., Schmid-Burgh W., Holzmuller B. Low cerebrospinal fluid glutamate levels in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
14. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremer J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetetive NMDA antagonist ketamine in humans. Arch. Gen. Psychiatry. 51:1994;199-214.
15. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsyhopharmacology. 13:1995;9-19.
16. Lannes B., Micheletti G., Warter J.-M., Kempf E., Di Scala G. Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat. Neurosci. Lett. 128:1991;177-181.
17. Laprade N., Soghomonian J.-J. MK-801 decreases striatal and cortical GAD65 mRNA levels. NeuroReport. 6:1995;1885-1889.
18. Lieberman J.A., Kinon B.J., Loebel A.D. Dopaminergic mechanisms in idiopatic and drug-induced psychosis. Schizophrenia Bull. 16:1990;97-110.
19. Löscher W., Annies R., Hönack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128:1991;191-194.
20. Löscher W., Hönack D. The behavioural effects of MK-801 in rats: Involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol. 215:1992;199-208.
21. 2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartatic acid. Eur. J. Pharmacol. 256:1994;23-30.
22. O'Connor W.T., Morari M., Fuxe K., Ungerstedt U. Dopamine and NMDA regulation of striatal GABAergic output neurons. Louilot A., Durkin T. Monitoring Molecules in Neuroscience. 1994;289-290 Proc. 6th Int. Conf. on In Vivo Methods in Seignosse "Les Tuquets" France.
23. Œye I., Paulsen O., Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 260:1992;1209-1213.
24. Parada-Turska J., Turski W.A. Excitatory amino acid antagonists and memory: effects of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks. Neuropharmacology. 29:1990;1111-1116.
25. Parks S., Holzman P. Schizophrenics show spatial working memory deficits. Arch. Gen. Psychiatry. 49:1992;975-982.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd edn. 1986;Academic Press Inc. San Diego, CA.
27. Qin Z.H., Zhang S.P., Weiss B. Dopaminergic and glutamatergic blocking drugs differentially regulate glutamic acid decarboxylase mRNA in mouse brain. Mol. Brain Res. 21:1994;293-302.
28. Robinson T.E., Becker J.B. Enduring changes in brain and behaviour produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11:1986;157-198.
29. Roth B.L., Meltzer H.Y. The role of serotonin in schizophrenia. Bloom F.E., Kupfer D.J. Psychopharmacology: the Fourth Generation of Progress. 1995;1215-1227 Raven Press, New York.
30. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry. 52:1995;805-818.
31. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., Waziri R. Evidence of a glutamatergic deficiency in schizophrenia. Neurosci. Lett. 121:1991;77-80.
32. Smith D.J., Azzaro A.J., Zaldivar S.B., Palmer S., Lee H.S. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology. 20:1981;391-396.
33. Taylor M.A., Abrams R. Cognitive impairment in schizophrenia. Am. J. Psychiatry. 141:1984;196-201.
34. Thomson A.M., Wets D.C., Lodge D. An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature. 313:1985;479-481.
35. Toru M., Kurumaji A., Ishimaru M. Excitatory amino acids: implications for psychiatric disorders research. Life Sci. 55:1994;1683-1699.
36. Tsai G.T., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry. 52:1995;829-836.
37. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand., Suppl. 367:1971;69-93.
38. Ungerstedt U. Measurements of neurotransmitter release by intracranial dialysis. Marsden C.A. Measurements of Neurotransmitter Release in vivo. 1984;81-105 Wiley and Sons, New York.
39. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16:1996;373-379.
40. Wedzony K., Klimek V., Golembiowska K. MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res. 622:1993;325-329.
41. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorso-lateral prefrontal cortex in schizophrenia. Arch. Gen. Psychiatry. 45:1988;609-615.
42. Williams G.V., Goldman-Racik P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 376:1995;572-575.
43. Zukin S.R., Zukin R.S. Phencyclidine. Lowinson J.H., Ruiz P.R., Millman R.B., Langrod J.G. Substance Abuse, 2nd edn. 1992;290-302 Williams and Wilkins, Baltimore.